The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
Open accessAbstract
Background: Coronavirus disease-2019 (COVID-19) has a wide range of pathophysiological effects. Curcumin, an active constituent of Curcuma longa (turmeric), has several properties, including anti-inflammatory, antioxidant, antiviral, anti-thrombotic, and anti-proliferative effects, which make it a promising candidate for the symptomatic treatment of COVID-19. Objective: We aimed to determine the effects of curcumin administered with piperine (to optimize absorption) on symptoms in patients with COVID-19 in a double-blind, randomized, controlled trial at a 30-bed dedicated COVID Health Center (DCHC) in Maharashtra, India. Methods: In addition to conventional COVID-19 treatment, patients in the control group received a dose of probiotics twice a day, and patients in the study group received curcumin (525 mg) with piperine (2.5 mg) in tablet form twice a day. The effects of curcumin/piperine treatment on primary and secondary outcomes were assessed for the duration of hospitalization. Results: Patients with mild, moderate, and severe symptoms who received curcumin/piperine treatment showed early symptomatic recovery (fever, cough, sore throat, and breathlessness), less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to patients of the control group. Furthermore, curcumin/piperine treatment appeared to reduce the duration of hospitalization in patients with moderate to severe symptoms, and fewer deaths were observed in the curcumin/piperine treatment group. Conclusions: Administration of oral curcumin with piperine as an adjuvant symptomatic therapy in COVID-19 treatment could substantially reduce morbidity and mortality, and ease the logistical and supply-related burdens on the healthcare system. Curcumin could be a safe and natural therapeutic option to prevent Post-Covid thromboembolic events. Clinicaltrials.gov identifier:CTRI/2020/05/025482
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Curcumin: A Review of Its Effects on Human Health
Hewlings, S., & Kalman, D. (2017) · Foods · doi:10.3390/foods6100092 · Cited by 2,720
Cited by
Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., Hu, C., & Xu, R. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s327378 · Cited by 827
Curcumin: Biological Activities and Modern Pharmaceutical Forms
Urošević, M., Nikolić, L., Gajić, I., Nikolić, V., Dinić, A., & Miljković, V. (2022) · Antibiotics · doi:10.3390/antibiotics11020135 · Cited by 347
El-Saadony, M. T., Yang, T., Korma, S. A., Sitohy, M., Abd El-Mageed, T. A., Selim, S., Al Jaouni, S. K., Salem, H. M., Mahmmod, Y., Soliman, S. M., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1040259 · Cited by 330
Biomedical Applications and Bioavailability of Curcumin—An Updated Overview
Sohn, S.-I., Priya, A., Balasubramaniam, B., Muthuramalingam, P., Sivasankar, C., Selvaraj, A., Valliammai, A., Jothi, R., & Pandian, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122102 · Cited by 305
Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c07326 · Cited by 301
Metadata
- Authors
- Pawar, K. S., Mastud, R. N., Pawar, S. K., Pawar, S. S., Bhoite, R. R., Bhoite, R. R., Kulkarni, M. V., & Deshpande, A. R.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-05-28
- Volume
- 12
- Pages
- 669362-669362
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3170178772
- Cited by
- 178
- References
- 2
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.3389/fphar.2021.669362
- The paper
- Pawar, K. S., Mastud, R. N., Pawar, S. K., Pawar, S. S., Bhoite, R. R., Bhoite, R. R., Kulkarni, M. V., & Deshpande, A. R. (2021). Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.669362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.